Wolverine Asset Management’s PTC Therapeutics PTCT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-3,900
Closed -$145K 1773
2024
Q3
$145K Sell
3,900
-5,500
-59% -$184K ﹤0.01% 1064
2024
Q2
$287K Sell
9,400
-21,900
-70% -$709K ﹤0.01% 944
2024
Q1
$911K Sell
31,300
-4,700
-13% -$132K 0.01% 676
2023
Q4
$992K Buy
36,000
+18,700
+108% +$428K 0.01% 716
2023
Q3
$388K Buy
+17,300
New +$643K ﹤0.01% 940
2023
Q1
Sell
-6,600
Closed -$252K 2051
2022
Q4
$252K Hold
6,600
﹤0.01% 1099
2022
Q3
$331K Buy
+6,600
New +$323K ﹤0.01% 1132
2019
Q1
Sell
-12,700
Closed -$435K 1652
2018
Q4
$435K Hold
12,700
0.01% 1064
2018
Q3
$596K Hold
12,700
0.01% 972
2018
Q2
$428K Buy
12,700
+2,700
+27% +$84.2K 0.01% 974
2018
Q1
$270K Sell
10,000
-19,800
-66% -$502K ﹤0.01% 1097
2017
Q4
$497K Buy
+29,800
New +$504K 0.01% 904

Other funds holding PTCT

Wolverine Asset Management's PTCT Position: Q4 2025 in Review

Wolverine Asset Management sold out of PTC Therapeutics (PTCT) in Q4 2025, closing a stake of 24,392 shares — an estimated $1.5M sold.

Wolverine Asset Management first reported a position in PTCT in Q2 2025 and held it in 2 quarters. The position peaked at $1.5M in Q3 2025. 352 funds tracked by Wall St. Rank hold PTCT as of Q4 2025.

  • Wolverine Asset Management reported no remaining PTC Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Wolverine Asset Management sold 24,392 PTC Therapeutics shares in Q4 2025, an estimated $1.5M.
  • Wolverine Asset Management first reported a position in PTC Therapeutics in Q2 2025 and held it in 2 quarters.
  • Wolverine Asset Management's PTC Therapeutics position peaked at $1.5M in Q3 2025.
  • 352 funds tracked by Wall St. Rank held PTC Therapeutics as of Q4 2025.

Based on Wolverine Asset Management's 13F filing for Q4 2025, filed 2 Feb 2026.